Clinical trial
Biological Therapy in Treating Patients With Myelodysplastic Syndrome
NCT00005853 · Fred Hutchinson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00005853 |
|---|---|
| Title | Biological Therapy in Treating Patients With Myelodysplastic Syndrome |
| Official title | Therapy of Myelodysplastic Syndrome (MDS) With Antithymocyte Globulin (ATG) and TNFR:Fc |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Biological |
| Interventions | anti-thymocyte globulin, etanercept |
| Start date | Dec 1, 1999 |
| Primary completion | Aug 1, 2005 |
| Completion | Aug 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 2, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: